As the calendar turned from April to May, a big change came to the FDA. | Katherine Szarama, Ph.D., will take over as CBER ...
In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...
NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy development and manufacturing, today announced its strong scientific and commercial presence at the American ...
The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for ...
The FDA proposed Thursday not adding three active ingredients in weight-loss drugs to its so-called bulks list.
Fresh vaccine chief joins FDA; Psychiatrists debate overprescribing causes; Health authorities anticipate measles uptick this ...
Just The News on MSNOpinion
Mainstream media ignore FDA COVID vaccine injury whistleblower, hype questionable safety studies
"The people talking to [New York Times reporter] Christina Jewett certainly know that inherent flaw" in self-controlled case ...
The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other ...
The FDA and EMA have set out updated regulatory agendas that will shape biologics manufacturing standards in coming years. The FDA’s Center for Biologics Evaluation and Research (CBER) 2026 agenda ...
Qure’s fair value estimate has been adjusted from US$37.84 to US$38.48, a small move that still reflects meaningful debate ...
ClearPoint faces pressure from weak 2026 guidance and regulatory uncertainty, but partner therapy launches could drive ...
US drug pricing policy and Congressional Budget Office (CBO) model of the Build Back Better Act examining pharmaceutical R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results